Pfizer said that the prefilled dual-chamber syringe is used to administer Xyntha intravenously (IV) after reconstitution of a freeze-dried powder with the diluent (0.9% Sodium Chloride). For the first time, both the Xyntha powder and the diluent are supplied within the prefilled dual-chamber syringe.
Pfizer added that the prefilled dual-chamber syringe is expected to provide 3000IU of Xyntha in a low 4ml volume.
Emil Andrusko, vice president of marketing of specialty biologics at Pfizer, said: “The approval of the prefilled dual-chamber syringe is an important milestone for hemophilia patients due to its convenient reconstitution system that eliminates the transfer step.”
Sue Geraghty, nurse coordinator at University of Colorado School of Medicine Hemophilia and Thrombosis Center, said: “As an all-inclusive, travel-ready kit, the prefilled dual-chamber syringe offers patients with hemophilia A convenience in reconstituting Xyntha, saving them both time and effort.”
